SCHEMBL30659144

SCHEMBL30659144

CCOC(=O)Cc1ccc2nc(NC(=O)CC(C)(C)C)n(C3CCC3)c2c1F

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 1/20 0.38
▸ MAPK1 P28482 1/20 0.38
▸ OPRM1 P35372 2/20 0.35
▸ OPRK1 P41145 2/20 0.35
▸ OGFRL1 Q5TC84 2/20 0.35
▸ NPSR1 Q6W5P4 2/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ CCND1 P24385 1/20 0.34
▸ CCNE1 P24864 1/20 0.34
▸ CDK2 P24941 1/20 0.34
▸ CDK6 Q00534 1/20 0.34
▸ EGFR P00533 3/20 0.34
▸ MET P08581 1/20 0.33
▸ ALK Q9UM73 1/20 0.33
▸ ALDH1A1 P00352 4/20 0.33
▸ RORC P51449 1/20 0.32
▸ CYP3A4 P08684 2/20 0.32
▸ CYP2C9 P11712 2/20 0.32
▸ HDAC4 P56524 1/20 0.32
▸ HDAC6 Q9UBN7 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17582767 1.00 MAPT (0.38) MAPTMAPK1OPRM1OPRK1OGFRL1
SCHEMBL30659118 0.88 EGFR (0.34) OPRM1OPRK1OGFRL1EGFRALK
SCHEMBL17582797 0.88 EGFR (0.34) OPRM1OPRK1OGFRL1EGFRALK
SCHEMBL17583019 0.88 EGFR (0.34) EGFRALKCYP3A4CYP2C9CYP2D6
SCHEMBL25919584 0.86 MAPT (0.35) MAPTMAPK1OPRM1OPRK1OGFRL1
SCHEMBL25922209 0.84 MAPT (0.35) MAPTMAPK1OPRM1OPRK1OGFRL1
SCHEMBL17582769 0.84 ALK (0.35) OPRM1OPRK1OGFRL1EGFRALK
SCHEMBL25922214 0.84 OPRM1 (0.35) MAPTMAPK1OPRM1OPRK1OGFRL1
SCHEMBL20209791 0.84 EGFR (0.34) OPRM1OPRK1OGFRL1EGFRALK
SCHEMBL23559787 0.83 OPRM1 (0.34) MAPTMAPK1OPRM1OPRK1OGFRL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12351559-B2 Benzoimidazol benzomidazol-1,2-yl amides as Kv7 channel activators BIOHAVEN THERAPEUTICS LTD. (VG) 2025-07-08 — — US disclosed
US-20240300903-A1 BENZOMIDAZOL-1,2-YL AMDES AS Kv7 CHANNEL ACTIVATORS BIOHAVEN THERAPEUTICS LTD (US) 2024-09-12 — — US disclosed
US-11834418-B2 Benzoimidazol-1,2-yl amides as Kv7 channel activators BIOHAVEN THERAPEUTICS LTD. (VG) 2023-12-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11834418-B2 Benzoimidazol-1,2-yl amides as Kv7 channel activators KCNA7, KCNJ2, KCNK17 MAPT 2988/4885MAPK1 1037/4885OPRM1 1026/4885
US-20240300903-A1 BENZOMIDAZOL-1,2-YL AMDES AS Kv7 CHANNEL ACTIVATORS KCNA7, KCNK17, KCNK2 MAPT 2817/4885MAPK1 825/4885OPRM1 844/4885
US-12351559-B2 Benzoimidazol benzomidazol-1,2-yl amides as Kv7 channel activators KCNA7, KCNJ2, KCNK17 MAPT 2655/4885MAPK1 1036/4885OPRM1 1222/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback